Acerta Pharma B.V. et al v. Alembic Pharmaceuticals Limited et al > Summary
Court Case Number 1:23-cv-00548
Filing Date May 19, 2023
Court Delaware District Court
Status Unknown
JudgesGregory B. Williams
Plaintiff Attorneys
12AstraZeneca
Attorney Name: Daniel M. Silver
McCarter & English
AstraZeneca
Attorney Name: Alexandra M. Joyce
McCarter & English
Merck Sharp & Dohme
Attorney Name: Daniel M. Silver
McCarter & English
Merck Sharp & Dohme
Attorney Name: Alexandra M. Joyce
McCarter & English
Merck Sharp & Dohme
Attorney Name: Daniel M. Silver
McCarter & English
Merck Sharp & Dohme
Attorney Name: Alexandra M. Joyce
McCarter & English
Merck Sharp & Dohme
Attorney Name: Daniel M. Silver
McCarter & English
Merck Sharp & Dohme
Attorney Name: Alexandra M. Joyce
McCarter & English
Merck Sharp & Dohme
Attorney Name: Daniel M. Silver
McCarter & English
Merck Sharp & Dohme
Attorney Name: Alexandra M. Joyce
McCarter & English
Merck Sharp & Dohme
Attorney Name: Daniel M. Silver
McCarter & English
Merck Sharp & Dohme
Attorney Name: Alexandra M. Joyce
McCarter & English
Defendant Attorneys
2Related Patents
Doc No | Title | Issue date |
---|---|---|
10272083 | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor | Apr 30, 2019 |
10239883 | 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors | Mar 26, 2019 |
10167291 | Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl) pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide | Jan 1, 2019 |
09758524 | 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors | Sep 12, 2017 |